Innovative CAR T-Cell Therapy Shows Promise in Treating Glioblastoma
In a groundbreaking development, researchers at Mass General Cancer Centre have reported a remarkable regression in tumor size in a 72-year-old man with glioblastoma after receiving CAR T-cell therapy. Glioblastomas are aggressive and deadly brain cancers that claim the lives of up to 95 percent of patients within five years of diagnosis.
CAR T-cell therapy works by re-engineering a patient’s T-cells to target identifying surface markers on cancer cells. Preclinical laboratory trials showed promising results in targeting glioblastomas and recruiting other T-cells to fight the cancer.
The success of the therapy was highlighted in a phase 1 clinical trial called INCIPIENT, which evaluated the safety and potential of CARv3-TEAM-E T-Cells in patients with glioblastoma. While two other patients did not see as positive outcomes, the case of the 72-year-old man is promising for finding a cure for glioblastoma.
Published in The New England Journal of Medicine, the report emphasizes the success of targeting EGFR as an immunotherapeutic target in glioblastoma. Researchers are optimistic about the potential of CAR T-cell therapy as a novel approach in treating this deadly cancer.
Although the long-term prognosis is still unknown, further study and clinical trials could offer hope for patients with the deadliest of cancers. The success of CAR T-cell therapy in targeting glioblastomas marks a significant advancement in the field of immunotherapy and brings new hope to those battling this aggressive disease.
“Travel aficionado. Incurable bacon specialist. Tv evangelist. Wannabe internet enthusiast. Typical creator.”